Innovative Approaches to Prevent and Treat Fracture Related Infection

Friday, October 20, 2023

4:30 PM – 5:30 PM PST

Location: 6B

Moderator(s)

RO

Robert V. O'Toole, MD

Professor, Orthopaedic Surgery
University of Maryland School of Medicine, R Adams Cowley Shock Trauma Center
Baltimore, Maryland, United States

Disclosure(s): imagen: Consultant (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); lincotek: Other Financial or Material Support (Ongoing); stryker: Consultant (Ongoing)
JD

James Doub, MD

Assistant Professor
University of Maryland School of Medicine
baltimore, Maryland, United States

Disclosure(s): Adaptive Phage Therapeutics: Consultant (Terminated, January 30, 2022); Kane Biotech: Consultant (Ongoing)

Faculty(s)

JD

James Doub, MD

Assistant Professor
University of Maryland School of Medicine
baltimore, Maryland, United States

Disclosure(s): Adaptive Phage Therapeutics: Consultant (Terminated, January 30, 2022); Kane Biotech: Consultant (Ongoing)
LG

Leah Gitajn, MD, MS

Associate Professor
Dartmouth-Hitchcock Medical Center
Hanover, New Hampshire, United States

Disclosure(s): STRYKER: Consultant (Ongoing)
EM

Emily Ann McClure, PhD, MS (she/her/hers)

PostDoctoral Research Associate
Geisel School of Medicine at Dartmouth College
Hanover, New Hampshire, United States

Disclosure(s): No financial relationships to disclose
Roman M. Natoli, MD, PhD

Indiana University Health
Indianaopolis, Indiana, United States

Disclosure(s): No financial relationships to disclose
Jonathan T. Elliott, PhD

Assistant Professor & Senior Scientist
Dartmouth Health
Lebanon, New Hampshire, United States

Disclosure(s): No financial relationships to disclose

There are multiple innovative emerging and novel interventions to prevent, diagnose, and treat Fracture Related Infection which have the potential to revolutionize how we care for patients. However, at the present, the broad orthopaedic trauma community has had minimal exposure to these new approaches. The aim of this proposal is to outline emerging and novel strategies which are likely to impact treatment strategies in the near- and medium-term.

Infection after high-energy open fracture is one of the most challenging and common complications facing trauma patients and their orthopaedic surgeons with an estimated annual cost of $35 billion in the US. Infection requires unplanned surgical procedures and leads to prolonged morbidity, loss of function and potential loss of limb. The treatment of patients with open fracture involves IV abx and operative debridement just as it did 50 years ago. Despite universal application of these interventions, the rate of infection remains unacceptably high for the past 20 years for the most severe open fractures at approximately 30%. This session is aimed at addressing new techniques to address this unsolved problem.

Learning Objectives:

At the completion of this activity, participants will be able to:

Provide the orthopaedic trauma community with an overview of promising emerging strategies designed to prevent and treat infection which are likely to be translated into clinical practice in the near-term.
Provide the orthopaedic trauma community with an overview of promising novel strategies designed to prevent and treat infection which may be ready for translation into clinical practice in the medium-term.
Discuss potential barriers and expected impact of these treatment strategies on the field of orthopaedic trauma.